Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2Phase 3 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 54Genitourinary 29Other hematologic neoplasm 16Plasma cell 5Tumor-Agnostic 4Myeloid 4Dermatologic 4Thoracic 3Other solid neoplasm 2Gynecologic 2Breast 2Sarcoma 1Other neoplasm 1Gastrointestinal 1Classical hematology 1

Conditions

Triple Negative Breast Neoplasms 1Prostatic Neoplasms 1Neoplasms 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1

Interventions

Paclitaxel 100Trastuzumab 81pembrolizumab 76Fulvestrant 68Cyclophosphamide 66Carboplatin 47Capecitabine 47Docetaxel 45palbociclib 41Lapatinib 40Letrozole 37Doxorubicin 29olaparib 28Taxes 28Nivolumab 25Magnetic Resonance Spectroscopy 25Gemcitabine 25130-nm albumin-bound paclitaxel 25Everolimus 23Biopsy 23ribociclib 22abemaciclib 21Specimen Handling 21Albumin-Bound Paclitaxel 21Radiotherapy 19Cisplatin 19Bevacizumab 19Ado-Trastuzumab Emtansine 19pertuzumab 17Alpelisib 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Prednisone × Breast × Clear all
NCT02776436 2026-02-17

REDEX

Leiden University Medical Center

Phase 1 Completed
46 enrolled
BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT04726332 2024-05-14

Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)

Exelixis

Phase 1 Terminated
52 enrolled
BreastGynecologic

Carcinoma, Ovarian Epithelial, Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡